<DOC>
	<DOCNO>NCT02395913</DOCNO>
	<brief_summary>Acebrophylline metabolize separated Ambroxol 7-theophylline orally administer salt compose acid-base compound synthesize chloride ( salifying ) ambroxol 7-theophylline . Acebrophylline selectively apply bronchial lung tissue inhibit activity phospholipase bronchoalveolar show expectorant action raise surface activity alveolar , leukotrienes ( LTs ) suppress production prostaglandin ( PGs ) , show potent anti-inflammatory activity , bronchial celebrate reduce bronchial hyperreactivity normal state allow recuperate extend . It develop improve compliance improve pharmaceutically Surfolase capsule ( Acebrophylline 100mg ) intake twice daily 100mg Surfolase CR ( Acebrophylline 200mg ) intake daily 200mg</brief_summary>
	<brief_title>Compare Safety Pharmacokinetic Properties Surfolase Capsule ( Acebrophylline 100mg ) Surfolase CR ( 200mg )</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male subject age 20 55 year , BMI &gt; 18.5 , &lt; 25 , inclusive *Body mass index ( kg/m2 ) = weight ( kg ) /height ( ) 2 2 . Subject n't congenital chronic disease abnormal medical examination result . 3 . Subject healthy ( clinically relevant finding investigation preexamination ) judge investigator 4 . Subjects sign date informed consent form indicate subject decide participate study inform pertinent aspect study 1 . Subject know hypersensitivity reaction acebrophylline , xanthine food . 2 . Patients genetic problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 3 . Subject serious active cardiovascular , respiratory , hepatologic , renal , hematologic , gastrointestinal , immunologic , dermal , neurologic , psychological disease history disease 4 . Subject known history gastrointestinal disease gastrointestinal surgery affect absorption drug 5 . Subjects follow condition screen ( blood pressure , 12lead ECG , blood , urinalysis , etc . ) 6 . Subject follow condition laboratory test i. AST ( sGOT ) ALT ( sGPT ) &gt; Upper normal limit × 1.25 ii . Total bilirubin &gt; Upper normal limit × 1.5 7 . If estimate GFR &lt; 80mL/min/1.76m2 use MDRD formula . 8 . Systolic blood pressure &lt; =90mmHg diastolic blood pressure &gt; =150mmHg person show corresponding figure &lt; =50mmHg &gt; =100mmHg vital sign . 9. Who history drug abuse ( especially hypnotic , central act analgesic , psychotropic drug , opiates central nervous system act drug ) show positive reaction drug abuse urine drug screening test . 10 . Excessive caffeine alcohol intake , smoke person ( caffeine : &gt; 5cups/day , alcohol : &gt; 210g/week , tobacco : &gt; 10 cagarettes/day ) 11 . Use prescription medication within 14 day prior study medication dosing use medication overthecounter medication include oriental medication within 7 day prior study medication dose 12 . Participation clinical investigation within 60days prior study medication dose 13 . Subjects whole blood donation within 60days , component blood donation within 30days 14 . Subjects decision nonparticipation investigator 's review due laboratory test result excuse nonresponding request instruction investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>